Cargando…
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study
BACKGROUND: Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn’s disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota...
Autores principales: | Rob, Filip, Schierova, Dagmar, Stehlikova, Zuzana, Kreisinger, Jakub, Roubalova, Radka, Coufal, Stepan, Mihula, Martin, Jackova, Zuzana, Kverka, Miloslav, Thon, Tomas, Kostovcikova, Klara, Bajer, Lukas, Drastich, Pavel, Hercogova, Jana Tresnak, Novakova, Michaela, Kolar, Martin, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803183/ https://www.ncbi.nlm.nih.gov/pubmed/36584073 http://dx.doi.org/10.1371/journal.pone.0277576 |
Ejemplares similares
-
Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
por: Coufal, Stepan, et al.
Publicado: (2023) -
Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy
por: Reiss, Zuzana, et al.
Publicado: (2023) -
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
por: Schierova, Dagmar, et al.
Publicado: (2021) -
Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response
por: Coufal, Stepan, et al.
Publicado: (2019) -
Dysbiosis of Skin Microbiota in Psoriatic Patients: Co-occurrence of Fungal and Bacterial Communities
por: Stehlikova, Zuzana, et al.
Publicado: (2019)